For the first time in its history, Celcuity heads into an earnings report where the most important number may be on the top line rather than the bottom. Revtropik won FDA approval in July for second-line, PIK3CA wild-type HR-positive, HER2-negative advanced breast cancer, and management said commercial shipments would begin late in the third quarter. The September-quarter report, due after the close on November 5, should show whether that timeline held and whether the launch has actually started.
Wall Street is braced for a loss of $1.47 per share, slightly wider than the $1.44 lost last quarter and about 60% deeper than the $0.92 loss a year ago. That widening is no surprise. Selling, general and administrative spending roughly doubled sequentially to $35 million last quarter as the company deployed 88 oncology sales specialists, and the full cost of that field force should land in this period. Consensus revenue of $2.3 million is a modest first marker. At the $30,000 wholesale price per cycle and the roughly 20% gross-to-net discount management outlined, that works out to something near 95 cycles of therapy, a figure that could be distorted in either direction by initial distributor stocking. The company has not issued formal revenue guidance, so the Street is essentially estimating how many weeks of selling fit into the quarter.
That makes the manufacturing question the first thing to check. Management tied the start of shipments to FDA clearance of a second manufacturing site, and on the last call analysts pressed repeatedly on launch confidence because no formal sign-off had been confirmed. Revenue in line with or above consensus, along with confirmation that the site is cleared, would validate the story management told in August. A slip in first shipments into the fourth quarter, or vague language about the site, would challenge it far more than any EPS variance.
Beyond the launch, several promised milestones deserve an update. Management planned to submit a supplemental application for the PIK3CA-mutant cohort in the third quarter, following ASCO data showing median progression-free survival of about 11 months versus 5.6 months for alpelisib plus fulvestrant. That filing underpins the expanded market opportunity of more than $6 billion. Investors should also look for European and Japanese filing timing, progress on the 300mg prostate program ahead of data expected this quarter, and early signals on reimbursement. Notably, management stopped reiterating its earlier peak-sales estimate of up to $2.5 billion to $3 billion last quarter; whether it returns, or stays absent, will say something about internal confidence.
The market has turned skeptical despite the approval. Shares have fallen 16.4% since the last report, lagging the S&P 500 by more than 15 points, and sentiment has swung from mildly bullish to firmly bearish. At about $69, the stock sits well below its 200-day moving average near $101 and in the lower half of a post-earnings range spanning roughly $54 to $98, a range that sits entirely below the prior quarter's. Some of that pessimism likely reflects the inherent murkiness of an IV, buy-and-bill launch, where management warned demand data lag two to three months and capture only part of the patient base. With $754 million in cash and runway into 2029, financing is not the worry; execution is.
Ultimately, this report hinges on proof that Revtropik is reaching patients on schedule. If the second site is cleared, shipments began as promised and the mutant filing is in, the bearish drift looks overdone and the approval narrative stays intact. If any of those pieces is delayed, the quarter will reinforce the market's concern that the launch is starting slower than the science deserves.